Our Pipeline

Advanced Pipeline, Aggressive Timeline

At Anji, we focus on high-value, innovative projects that have been credentialed by human data. With a lean operational model that avoids bureaucracy and red tape, we can pursue the best ideas at the right time and work quickly and efficiently to help patients across the globe.

We Focus on What Works

Our custom-built portfolio prioritizes unmet need, without limitations on disease area or therapeutic modality.

Metabolic Disease Pipeline

Oncology Pipeline

ANJ810 MCL 1 inhibitor
Phase 1
Phase 2
Phase 3
Anji’s oncology programs are being developed by its subsidiary, Anji Onco, Inc.

What’s Happening at Anji

For partnerships, investment opportunities, or to learn more about our work, contact us.